Last reviewed · How we verify

NCT05166473

Effectiveness of Telerehabilitation Exercise for Bening Paroxysmal Positional Vertigo

Completed NA Last updated 12 July 2022
What this trial tests

NA trial testing Telerehabilitation group (n=21) in Benign Paroxysmal Vertigo in 42 participants. Completed in 30 January 2022.

Timeline
10 May 2021
Primary endpoint
30 November 2021
30 January 2022

Quick facts

Lead sponsorAlanya Alaaddin Keykubat University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment42
Start date10 May 2021
Primary completion30 November 2021
Estimated completion30 January 2022
Sites2 locations across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Alanya Alaaddin Keykubat University

Who can join

Adults 18 to 65, any sex, with Benign Paroxysmal Vertigo. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In addition to the channelize reposition maneuvers (KRM) that will be applied by the physician in patients diagnosed with Benign paroxysmal positional Vertigo (BPPV), the aim of the study is to investigate the effect of vestibular rehabilitation exercises that will be October based on telerehabilitation by the physiotherapist.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Are Telerehabilitation Exercise Practices Effective in Patients Diagnosed with Benign Paroxysmal Positional Vertigo?
    Haciabbasoğlu R, Araci A, Günizi H. · · 2023 · cited 2× · PMID 37200900 · DOI 10.1007/s12070-023-03631-6

Verify or expand the search:

Other Alanya Alaaddin Keykubat University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05166473.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing